Annals of Surgical Oncology

, Volume 8, Issue 10, pp 828–832

Estrogen Replacement Therapy After Breast Cancer: A 12-Year Follow-Up

  • George N. Peters
  • Tomasina Fodera
  • Jennifer Sabol
  • Stephen Jones
  • David Euhus
Article

DOI: 10.1007/s10434-001-0828-4

Cite this article as:
Peters, G.N., Fodera, T., Sabol, J. et al. Ann Surg Oncol (2001) 8: 828. doi:10.1007/s10434-001-0828-4

Abstract

Background: In the United States, estrogen replacement therapy ERT is discouraged in breast cancer survivors because of concerns that hormones may reactivate the disease. Because ERT can improve quality of life and decrease morbidity from osteoporosis and cardiovascular disease, however, this policy is increasingly being challenged.

Methods: From February to August 1995, 607 breast cancer survivors were interviewed concerning ERT usage. Sixty-four patients indicated they received some form of ERT after their breast cancer diagnosis. Medical records for these patients were analyzed for disease stage, surgical treatment, adjuvant treatment, estrogen and progesterone receptor status, date of initiation of ERT, type of ERT, recurrence, and final outcome. Patients receiving ERT were followed prospectively.

Results: Eight patients were excluded because they had used only vaginal cream ERT. The remaining 56 received ERT as conjugated estrogens, an estradiol patch, estropipate, or birth control pills. The median follow-up from diagnosis was 12.8 years range, 4.7–38.9 years. The median time on ERT since diagnosis was 6.4 years range, 1.0–20.9 years; 38% of the patients initiated ERT within 2 years of diagnosis. Estrogen receptors were positive in 28 74% of the 38 cases with available information. Pathological disease stage at time of diagnosis and treatment was 0 in 15 cases 27%, I in 27 48%, and II in 14 25%. Twenty-six patients 47% received adjuvant chemotherapy or hormonal therapy. One local recurrence and one contralateral breast cancer occurred during the follow-up period 13.5 and 9.6 years, respectively, with no regional or distant recurrences, for a 15-year actuarial disease-free survival rate of 92.5%. There were no breast cancer deaths.

Conclusions: Use of ERT in a cohort of breast cancer survivors with tumors of generally good prognosis was not associated with increased breast cancer events compared with non-ERT users, even over a long follow-up period.

Key Words

Breast cancer Recurrence Estrogen replacement therapy Prognosis 

Copyright information

© The Society of Surgical Oncology, Inc. 2001

Authors and Affiliations

  • George N. Peters
    • 1
    • 2
  • Tomasina Fodera
    • 1
  • Jennifer Sabol
    • 1
  • Stephen Jones
    • 1
  • David Euhus
    • 1
  1. 1.Center for Breast CareThe University of Texas Southwestern Medical Center at Dallas, Baylor University Medical CenterDallas
  2. 2.Center for Breast CareThe University of Texas Southwestern Medical Center at DallasDallas

Personalised recommendations